SCHEMBL17035142

SCHEMBL17035142

Nc1ccccc1-c1ccc(-c2ccccc2)c2ccccc12

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.70
HSD17B10 Q99714 4/20 0.70
L3MBTL1 Q9Y468 2/20 0.59
HPGD P15428 4/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
KDM4E B2RXH2 1/20 0.47
NPC1 O15118 1/20 0.47
GAA P10253 1/20 0.47
RAB9A P51151 1/20 0.47
MAP4K4 O95819 1/20 0.44
CSF1R P07333 1/20 0.44
FGFR1 P11362 1/20 0.44
PDGFRA P16234 1/20 0.44
LTK P29376 1/20 0.44
KDR P35968 1/20 0.44
MAPK8 P45983 1/20 0.44
CSNK1A1 P48729 1/20 0.44
LIMK1 P53667 1/20 0.44
CDK5 Q00535 1/20 0.44
ACVR1 Q04771 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13845100 0.84 ALDH1A1 (0.65) ALDH1A1HSD17B10L3MBTL1HPGDSMN1; SMN2
SCHEMBL24901300 0.84 ALDH1A1 (0.52) ALDH1A1HSD17B10L3MBTL1HPGDSMN1; SMN2
SCHEMBL29607177 0.83 ALDH1A1 (0.80) ALDH1A1HSD17B10L3MBTL1HPGDSMN1; SMN2
SCHEMBL606996 0.83 ALDH1A1 (0.80) ALDH1A1HSD17B10L3MBTL1HPGDSMN1; SMN2
SCHEMBL845163 0.83 ALDH1A1 (0.80) ALDH1A1HSD17B10L3MBTL1HPGDSMN1; SMN2
SCHEMBL29413803 0.83 ALDH1A1 (0.80) ALDH1A1HSD17B10L3MBTL1HPGDSMN1; SMN2
SCHEMBL25981 0.83 ALDH1A1 (1.00) ALDH1A1HSD17B10L3MBTL1HPGDSMN1; SMN2
SCHEMBL28465796 0.83 ALDH1A1 (1.00) ALDH1A1HSD17B10L3MBTL1HPGDSMN1; SMN2
SCHEMBL16623899 0.83 ALDH1A1 (0.77) ALDH1A1HSD17B10L3MBTL1HPGDSMN1; SMN2
SCHEMBL29407079 0.83 ALDH1A1 (1.00) ALDH1A1HSD17B10L3MBTL1HPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9871208-B2 Condensed cyclic compound and organic light-emitting device including the same SAMSUNG DISPLAY CO., LTD. (KR) 2018-01-16 US disclosed
US-9871208-B2 Condensed cyclic compound and organic light-emitting device including the same SAMSUNG DISPLAY CO., LTD. (KR) 2018-01-16 US disclosed
US-20150243908-A1 CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME SAMSUNG DISPLAY CO., LTD. (KR) 2015-08-27 US disclosed
US-20150243908-A1 CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME SAMSUNG DISPLAY CO., LTD. (KR) 2015-08-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150243908-A1 CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME CRY1, CRY2, CCNE2 ALDH1A1 753/4885HSD17B10 2233/4885L3MBTL1 1123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.